Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rubicon ResearchNSE:RUBICON +0.36%19 14-Day RSI is 65.33 as of Sep. 03, 2026. GuruFocus rates NSE:RUBICON with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 1,047 Drug Manufacturers companies, Rubicon Research ranks worse than 90.64% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-09-03), Rubicon Research's 14-Day RSI is 65.33.
The industry rank for Rubicon Research's 14-Day RSI or its related term are showing as below:
NSE:RUBICON's 14-Day RSI is ranked worse than 90.64% of 1047
companies
in the Drug Manufacturers industry
Industry Median: 49.46
vs NSE:RUBICON: 65.33
Rubicon Research (NSE:RUBICON) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Rubicon Research 14-Day RSI Related Terms
NSE:RUBICON vs LLY, JNJ, ABBV: 14-Day RSI Comparison
For the Drug Manufacturers - General subindustry, Rubicon Research's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Research 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Rubicon Research's 14-Day RSI falls into.
Rubicon Research (NSE:RUBICON) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rubicon Research (NSE:RUBICON) has a 14-Day RSI of 65.33 as of Sep. 03, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Rubicon Research and its competitors. According to the industry distribution chart, Rubicon Research ranks #949 out of 1047 companies in the Drug Manufacturers industry, placing it in the top 90.6%.
Is Rubicon Research's 14-Day RSI too high?
Rubicon Research's current 14-Day RSI is 65.33. The Drug Manufacturers industry median 14-Day RSI is 49.46. Rubicon Research's value of 65.33 is 32.1% above this industry median. Based on the distribution chart, Rubicon Research ranks #949 out of 1047 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Rubicon Research has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's 14-Day RSI compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #949 out of 1047 companies for 14-Day RSI. This places Rubicon Research in the lower half of its industry. The industry median 14-Day RSI is 49.46. Rubicon Research's value of 65.33 is 32.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 49.46, based on 1,047 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rubicon Research's current 14-Day RSI of 65.33 is 32.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Rubicon Research and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 49.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current 14-Day RSI is 65.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current 14-Day RSI of 65.33. The current 14-Day RSI is 65.33 and 32.1% above the Drug Manufacturers industry median of 49.46. Rubicon Research's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current 14-Day RSI is 65.33 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
19GF Score
Get the complete analysis for NSE:RUBICON
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RUBICON has been successfully added to your 
